Posted by Michael Wonder on 17 Aug 2022
PHARMAC estimates Trikafta could give people with CF another 27 years
17 August 2022 - PHARMAC has today published the record of advice from the May PTAC meeting to again consider Vertex’s application for funding of Trikafta – a medicine to treat the underlying cause of cystic fibrosis.
PHARMAC has also published its technology assessment report setting out its economic health analysis of Trikafta, and a summary of its assessment of the application for Trikafta including factors for consideration.
